Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)

(2014) William H. Krüger et al.   ANNALS OF HEMATOLOGY

A phase 1 study of the PI3K  inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

(2014) B. S. Kahl et al.   BLOOD

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

(2014) I. W. Flinn et al.   BLOOD

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC

(2013) Cyrille Touzeau et al.   ANNALS OF HEMATOLOGY

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

(2013) P. L. Zinzani et al.   ANNALS OF ONCOLOGY

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213

(2013) S. H. Bernstein et al.   ANNALS OF ONCOLOGY

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network†

(2013) C. Y. Cheah et al.   ANNALS OF ONCOLOGY

Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation

(2013) Ryan D. Cassaday et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Differences in gene expression and cytokine levels between newly diagnosed and chronic pediatric ITP

(2013) M. Jernas et al.   BLOOD

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

(2013) Andre Goy et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation

(2013) Carlo Visco et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B

(2013) Yi-Hsiang Huang et al.   JOURNAL OF CLINICAL ONCOLOGY

Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study

(2013) Franck Andre Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

(2013) Anna Laurell et al.   LEUKEMIA & LYMPHOMA

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma

(2012) L. Nygren et al.   BLOOD

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte

(2012) R. Delarue et al.   BLOOD

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

(2012) Christian H. Geisler et al.   BRITISH JOURNAL OF HAEMATOLOGY

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

(2012) C. Renner et al.   HAEMATOLOGICA

Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499

(2012) Mitchell R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

(2012) Michael Wang et al.   LANCET ONCOLOGY

Treatment of Older Patients with Mantle-Cell Lymphoma

(2012) H.C. Kluin-Nelemans et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

(2011) Francesco Merli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers

(2011) F. Zaja et al.   HAEMATOLOGICA

Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma

(2011) W. Lamm et al.   HAEMATOLOGICA

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

(2011) Stephen M Ansell et al.   LANCET ONCOLOGY

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

(2011) C. Tom Kouroukis et al.   LEUKEMIA & LYMPHOMA

Treatment of Younger Patients With Mantle Cell Lymphoma

(2011) Stéphanie Harel et al.   SEMINARS IN HEMATOLOGY

Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma

(2010) Jia Ruan et al.   CANCER

Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

(2010) V. Fernandez et al.   CANCER RESEARCH

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group

(2010) R. Gressin et al.   HAEMATOLOGICA

Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen

(2010) Sotirios Sachanas et al.   LEUKEMIA & LYMPHOMA

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

(2009) C. Pott et al.   BLOOD

Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma

(2009) Michael Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909

(2009) Lloyd E. Damon et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

(2009) Peter Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

(2008) A. Goy et al.   ANNALS OF ONCOLOGY

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients

(2008) Mars B. van ’t Veer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma

(2008) Stephen M. Ansell et al.   CANCER

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD